{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Use of GLP-1 Receptor Agonists in Patients with T2DM and Chronic Kidney Disease

Purpose of Activity

To provide information about how the differences between GLP-1 receptor agonists relate to patients with T2DM and CKD.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Discuss the physiologic relationship between diabetes mellitus, CKD, CVD, and GLP-1 RAs.
  2. Recognize desired and untoward effects and contraindications of GLP-1 RAs.
  3. Determine proper dosing of GLP-1 RAs.
Price: $17.95


  • ANCC 1.5 CH / 1.5 APH
  • DC - BON 1.5 CH
  • FL - BON 1.5 CH
  • GA - BON 1.5 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.

Awarded Advanced Pharmacology Hours

Test Code: NP0319B
Published: Mar 2019
Expires: 3/5/2021
Passing Score: 13/18 (72%)
Authors: Sarah Aldrich, PharmD; Emily Ashjian, PharmD, BCPS, BCACP